- Home
- COLL vs FPF Comparison
COLL vs FPF Comparison
Compare COLL & FPF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- COLL
- FPF
- Stock Information
- Founded
- COLL 2002
- FPF 2013
- Country
- COLL United States
- FPF United States
- Employees
- COLL N/A
- FPF N/A
- Industry
- COLL Biotechnology: Pharmaceutical Preparations
- FPF Trusts Except Educational Religious and Charitable
- Sector
- COLL Health Care
- FPF Finance
- Exchange
- COLL Nasdaq
- FPF Nasdaq
- Market Cap
- COLL 910.2M
- FPF 999.7M
- IPO Year
- COLL 2015
- FPF N/A
- Fundamental
- Price
- COLL $26.79
- FPF $17.49
- Analyst Decision
- COLL Strong Buy
- FPF
- Analyst Count
- COLL 5
- FPF 0
- Target Price
- COLL $43.60
- FPF N/A
- AVG Volume (30 Days)
- COLL 393.2K
- FPF 186.7K
- Earning Date
- COLL 05-08-2025
- FPF 01-01-0001
- Dividend Yield
- COLL N/A
- FPF 8.08%
- EPS Growth
- COLL 43.56
- FPF N/A
- EPS
- COLL 1.86
- FPF N/A
- Revenue
- COLL $631,449,000.00
- FPF N/A
- Revenue This Year
- COLL $19.96
- FPF N/A
- Revenue Next Year
- COLL $3.93
- FPF N/A
- P/E Ratio
- COLL $14.31
- FPF N/A
- Revenue Growth
- COLL 11.41
- FPF N/A
- 52 Week Low
- COLL $23.23
- FPF $13.91
- 52 Week High
- COLL $42.29
- FPF $18.09
- Technical
- Relative Strength Index (RSI)
- COLL 43.80
- FPF 49.63
- Support Level
- COLL $25.87
- FPF $16.91
- Resistance Level
- COLL $27.95
- FPF $17.50
- Average True Range (ATR)
- COLL 1.50
- FPF 0.40
- MACD
- COLL 0.05
- FPF 0.09
- Stochastic Oscillator
- COLL 69.33
- FPF 99.65
About COLL Collegium Pharmaceutical Inc.
Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Jornay, Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.
About FPF First Trust Intermediate Duration Preferred & Income Fund of Beneficial Interest
First Trust Inter Dur Pref& Income Fund is a diversified, closed-end management investment company. Its primary investment objective is to seek a high level of current income. Further, it has a secondary objective of capital appreciation. The Fund invests in the traditional preferred securities, hybrid preferred securities, floating rate & fixed-to-floating rate preferred securities, debt securities, convertible securities, and contingent convertible securities issued by U.S. and non-U.S. companies. Its investment portfolio includes industries such as Banks, Insurance, Capital Markets, Electric Utilities, Oil, Gas & Consumable Fuels, Food Products, and others.